Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01368536 · ClinicalTrials.gov registry record · Phase 4
Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 4
- Development phase
- 975
- Enrollment target
NCT01368536 is a Phase 4 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 975 participants.
The verdict
NCT01368536, a Phase 4 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 975 participants
- Enrollment target
Study Summary
This was a study to assess the safety and efficacy of Valturna and amlodipine or Valturna and chlorthalidone when compared to Valturna alone in patients with stage 2 hypertension and diabetes mellitus 2.
Interventions
- DRUG Chlorthalidone
- DRUG Amlodipine
- DRUG Placebo Capsule
- DRUG Valturna
- DRUG Placebo of Valturna Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 975 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01368536
The ClinicalTrials.gov registry entry for NCT01368536 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 975 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Chlorthalidone is the first listed.
NCT01368536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01368536 about?
NCT01368536 is a clinical study titled "Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes". This was a study to assess the safety and efficacy of Valturna and amlodipine or Valturna and chlorthalidone when compared to Valturna alone in patients with stage 2 hypertension and diabetes mellitus 2.
What is the current status of trial NCT01368536?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 975 participants. The study started on 2011-05. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01368536?
The interventions under investigation include: Chlorthalidone (DRUG), Amlodipine (DRUG), Placebo Capsule (DRUG), Valturna (DRUG), Placebo of Valturna Tablet (DRUG).
Who is sponsoring clinical trial NCT01368536?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.